

PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57		
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units		

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE XRAY-CHEST IMPRESSION NO ABNORMALITY DETECTED

ECG

ECG

NORMAL SINUS RHYTHM

MEDICAL HISTORY

RELEVANT PRESENT HISTORY	NOT SIGNIFICANT
RELEVANT PAST HISTORY	NOT SIGNIFICANT
RELEVANT PERSONAL HISTORY	NOT SIGNIFICANT
MENSTRUAL HISTORY (FOR FEMALES)	REGULAR
LMP (FOR FEMALES)	28/01/2024
OBSTETRIC HISTORY (FOR FEMALES)	G2,P2,A0,L2
LCB (FOR FEMALES)	2.5 YEARS
RELEVANT FAMILY HISTORY	NOT SIGNIFICANT
OCCUPATIONAL HISTORY	NOT SIGNIFICANT
HISTORY OF MEDICATIONS	NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS	1.53	mts
WEIGHT IN KGS.	66.8	Kgs
BMI	29	BMI & Weight Status as follows/sqmts Below 18.5: Underweight

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

Dr.Sahil .N.Shah Consultant Radiologist

P. V. Kapadia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 1 Of 24





View Report

13 🗉





Biological Reference Interval Units

PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : ASIJF210692321	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 09:49:29
NEW DELHI 110030	ABHA NO :	REPORTED :16/02/2024 13:13:57
8800465156		

Results

GENERAL EXAMINATION

<u>Final</u>

Test Report Status

MENTAL / EMOTIONAL STATE	NORMAL
PHYSICAL ATTITUDE	NORMAL
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT
BUILT / SKELETAL FRAMEWORK	AVERAGE
FACIAL APPEARANCE	NORMAL
SKIN	NORMAL
UPPER LIMB	NORMAL
LOWER LIMB	NORMAL
NECK	NORMAL
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER
THYROID GLAND	NOT ENLARGED
TEMPERATURE	NORMAL
PULSE	66/MIN
RESPIRATORY RATE	NORMAL

CARDIOVASCULAR SYSTEM

BP	126/84 MM HG (SITTING)
PERICARDIUM	NORMAL
APEX BEAT	NORMAL
HEART SOUNDS	S1, S2 HEARD NORMALLY
MURMURS	ABSENT

mm/Hg

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST MOVEMENTS OF CHEST BREATH SOUNDS INTENSITY BREATH SOUNDS QUALITY NORMAL SYMMETRICAL NORMAL VESICULAR (NORMAL)

Dr.Sahil .N.Shah Consultant Radiologist Dr.Priyank Kapadia Physician

P. V. Kapadia

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 2 Of 24





View Report

5 🗆





Patient Ref. No. 77500006371199

CODE/TANKE & ADDRESS CODE/TANKE & LO (MORIVMEEL F-703, LADO SARAL, MEHRAULISOUTH WEST DELUIT ACCESSION NO: 0221120002032 MARCENT HILL TOSS ADDRESS ACCESSION NO: 0221210002121 DRAWN : CRESSION NO: 0221210002121 CLENT MENT DD: ASSIF210692121 CLENT MENT DD: ASSIF210692121 ABBA AD : REPORTED : 16/02/2024 09:49:29 REPORTED : 16/02/2024 13:13:57 Test Report Status Final Results Biological Reference Interval Units ADDED SOUNDS ABSENT PER ABDOMEN APPEARAINCE NORMAL LUVER ADDED SOUNDS ABSENT CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL NOT ALFABLE SPLEEN NOT ALFABLE SPLEEN NORMAL CRAINAL NERVES CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CREDELLAR FUNCTIONS SENSORY SYSTEM MOTOR SYSTEM NORMAL NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL NORMAL BASIC EYE EXAMINATION DISTART VISION RIGHT EYE WITHOUT GLASSES S/12 NORMAL DISTART VISION RIGHT EYE WITHOUT GLASSES K/2 NORMAL MASCULOSKELET AL SYSTEM SPINE NORMAL DISTART VISION RIGHT EYE WITHOUT GLASSES K/2 NORMAL MASCULOSKIELT EYE WITHOUT GLASSES K/2 NORMAL	PATIENT NAME : ASIFJAHAN Q	URESHI		REF. DOCTOR	SELF		
F-203, LADO SARAT, MEHRAULISOUTH WEST DELIT Intervent of the second se			ACCESSION NO :	0321XB001093	AGE/SEX	:31 Years	Female
DELHI MILIHI MULEHI MULEHI DU ELENDE 10/02/2024 13:3:57 REPORTED 1:6/02/2024 13:3:57 Test Report Status Einal Results Biological Reference Interval Units ADDED SOUNDS ABSENT PER ABDOMEN APPEARANCE NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT G/12 GLASSES NEAR VISION RIGHT EYE WITHOUT G/12 CASSES NEAR VISION RIGHT EYE WITHOUT G		11	PATIENT ID :	ASIJF210692321	DRAWN	:	
NEW DELHU 110030 8800465156 ABMA NO : REPORTED :16/02/2024 13:13:57 Text Report Status Einal Results Biological Reference Interval Units ADDED SOUNDS ABSENT PER ABDOMEN APPEARANCE NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL SENSORY SYSTEM NORMAL CRANIAL NERVES NORMAL SENSORY SYSTEM SPINE		JUIH WEST	CLIENT PATIENT II	D:	RECEIVED	: 10/02/202	4 09:49:29
Test Report Status Einal Results Biological Reference Interval Units ADDED SOUNDS ABSENT PER ABDOMEN APPEARANCE NORMAL LIVER NOT PALPABLE SPLEEN NOT PALPABLE CRANAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANAL NERVES NORMAL SENSORY SYSTEM NORMAL GRERELAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MUSCULOSKELETAL SYSTEM NORMAL JOINTS NORMAL SPINE NORMAL JOINTS NORMAL SSIC EYE EXAMINATION 6/12 CLASSES NORMAL SINTS NORMAL SASIC EYE EXAMINATION 6/12 CLASSES NORMAL MEX VISION RIGHT EYE WITHOUT 6/12 CLASSES N/6 COLOUR VISION NORMAL		4	ABHA NO :		REPORTED	:16/02/202	4 13:13:57
ADDED SOUNDS ABSENT PER ABDOMEN APPEARANCE NORMAL LIVER NOT PALPABLE SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MOSCULOSKELETAL SYSTEM SPINE NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL	8800465156						
PER ABDOMEN APPEARANCE NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVESS NORMAL CRANIAL NERVESS NORMAL CRANIAL NERVESS NORMAL CREABELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL BUSCULOSKELETAL SYSTEM MUSCULOSKELETAL SYSTEM SPINE NORMAL DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NORMAL PREVIONE CONTINUES NORMAL PREVIONE CONTINUES NORMAL PREVI	Test Report Status <u>Final</u>		Results	Biologi	cal Reference	e Interval	Units
APPEARANCE NORMAL LIVER NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL SPINE NORMAL SESSER SPINE NORMAL SPINE NORMAL SESSER SPINE NORMAL SPINE NO	ADDED SOUNDS	,	ABSENT				
LIVER NOT PALPABLE SPLEEN NOT PALPABLE SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 1//6 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 PALE OF THE PALE PALE PALE NORMAL PALE AND PALE PALE PALE PALE PALE PALE PALE PALE PALE PALE PALE PALE	PER ABDOMEN						
SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT GLASSES N/6 COLOUR VISION	APPEARANCE	n	NORMAL				
SPLEEN NOT PALPABLE CENTRAL NERVOUS SYSTEM HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES GLASSES GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/2 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/2 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/2 GLASSES NEAR VISION RIGHT EYE WITHOUT GLASSES N/6 COLOUR VISION	LIVER	1	NOT PALPABLE				
HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL BASIC EVE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/12 GLASSES NEAR VISION LEFT EYE WITHOUT 10/6 COLOUR VISION NORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL M		I	NOT PALPABLE				
HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CRANIAL NERVES NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL SPINE NORMAL DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 NGASSES NEAR VISION RIGHT EYE WITHOUT 6/12 NGASSES NEAR VISION RIGHT EYE WITHOUT 10/6 NORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL MORMAL							
CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION LEFT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT N/6 COLOUR VISION NORMAL	CENTRAL NERVOUS SYSTEM						
CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NORMAL	HIGHER FUNCTIONS	1	NORMAL				
SENSOR'S SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NEAR VISION RIGHT EYE WITHOUT 10/6 GLASSES NA NORMAL Page 3 0f 24	CRANIAL NERVES	1	NORMAL				
MOTOR SYSTEM NORMAL REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT 1 N/6 GLASSES N/6 COLOUR VISION NORMAL Page 3 0f 24	CEREBELLAR FUNCTIONS	1	NORMAL				
REFLEXES NORMAL MUSCULOSKELETAL SYSTEM SPINE SPINE NORMAL JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT N/6 GLASSES NORMAL Page 3 Of 24	SENSORY SYSTEM	1	NORMAL				
MUSCULOSKELETAL SYSTEM SPINE NORMAL JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 0f 24	MOTOR SYSTEM	ı	NORMAL				
SPINE NORMAL NORMAL NORMAL SALE SALE SALE SALE SALE SALE SALE SA	REFLEXES	1	NORMAL				
SPINE NORMAL NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION PAGE 3 Of 24 Page 3 Of 24	MUSCIII OSKEI ETAL SYSTEM						
JOINTS NORMAL BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24 Page 3 Of 24		,	NORMAI				
BASIC EYE EXAMINATION DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT M/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24 Page 3 of 24							
DISTANT VISION RIGHT EYE WITHOUT 6/12 GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24		ľ	IORMAL				
GLASSES DISTANT VISION LEFT EYE WITHOUT 6/12 GLASSES NEAR VISION RIGHT EYE WITHOUT N/6 GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24 Page 3 Of 24	BASIC EYE EXAMINATION						
GLASSES NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24 Page 3 Of 24		ITHOUT	5/12				
GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES N/6 COLOUR VISION NORMAL Page 3 Of 24		HOUT 6	5/12				
COLOUR VISION NORMAL Privila Page 3 Of 24							
Page 3 Of 24							
	COLOUR VISION	ſ	NORMAL				
	5	p.v. Kopudia					Page 3 Of 24
Consultant Radiologist Physician	Dr.Sahil .N.Shah Consultant Radiologist	Dr.Priyank Kapadia Physician					
View Details View Report						View Detail	



PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF		
	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

SUMMARY

RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS RELEVANT NON PATHOLOGY DIAGNOSTICS **REMARKS / RECOMMENDATIONS**

NOT SIGNIFICANT NOT SIGNIFICANT S.CHOLESTEROL: - HIGH, LDL: - HIGH USG ABDOMEN: - FATTY LIVER S.CHOLESTEROL: - HIGH, LDL: - HIGH ADV:- LOW FAT DIET, REGULAR PHYSICAL EXERCISE URINE: - LEUKOCYTE ESTERASE DETECTED (++), WBC - HIGH, EPITHELIAL CELLS - HIGH

ADV:- DRINK PLENTY OF WATER, REPEAT URINE ANALYSIS AFTER 10 DAYS AND PHYSICIAN OPINION SOS

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S) REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE) RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

Dr.Sahil .N.Shah **Consultant Radiologist** P. V. Kepadia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 4 Of 24











PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : ASIJF210692321 CLIENT PATIENT ID:	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57	
Test Report Status Final	Results	Units	

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN FATTY LIVER

TMT OR ECHO CLINICAL PROFILE 2D ECHO:-

- 1) NORMAL CHAMBERS AND VALVES.
- 2) GOOD LV SYSTOLIC FUNCTION. LVEF 60%. NO RWMA AT REST.
- 3) NO MR, AR, TR.
- 4) NORMAL LV COMPLIANCE.
- 5) NO PAH.
- 6) NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.

7) IAS/IVS INTACT.

Interpretation(s) MEDICAL HISTORY- ************************************
THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Dr.Sahil .N.Shah Consultant Radiologist P. V. Kapadia

Dr.Priyank Kapadia Physician





View Report

Page 5 Of 24

View Details





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTO	R: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ASIJF210692321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 09:49:29
NEW DELHI 110030	ABHA NO :	REPORTED :16/02/2024 13:13:57
8800465156		
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units

HAEMATOLOGY - CBC				
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE)	
BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	13.0	12.0 - 15.0	g/dL	
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.84 High	3.8 - 4.8	mil/µL	
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	7.77	4.0 - 10.0	thou/µL	
PLATELET COUNT METHOD : COULTER PRINCIPLE	370	150 - 410	thou/µL	
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	40.6	36.0 - 46.0	%	
METHOD : CALCULATED MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	83.8	83.0 - 101.0	fL	
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	26.9 Low	27.0 - 32.0	pg	
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	32.0	31.5 - 34.5	g/dL	
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.6 High	11.6 - 14.0	%	
MENTZER INDEX METHOD : CALCULATED PARAMETER	17.3			
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	7.9	6.8 - 10.9	fL	
WBC DIFFERENTIAL COUNT				
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	57	40 - 80	%	
LYMPHOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	35	20 - 40	%	

Dr.Miral Gajera Consultant Pathologist









PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57

Test Report Status <u>Final</u>	Results	Biological Reference Interv	val Units
MONOCYTES	5	2.0 - 10.0	%
METHOD : OPTICAL IMPEDENCE & MICROCSOPY			
EOSINOPHILS	3	1.0 - 6.0	%
METHOD : OPTICAL IMPEDENCE & MICROCSOPY			
BASOPHILS	0	0 - 1	%
METHOD : IMPEDANCE			
ABSOLUTE NEUTROPHIL COUNT	4.43	2.0 - 7.0	thou/µL
METHOD : CALCULATED			
ABSOLUTE LYMPHOCYTE COUNT	2.72	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE MONOCYTE COUNT	0.39	0.2 - 1.0	thou/µL
METHOD : CALCULATED PARAMETER			
ABSOLUTE EOSINOPHIL COUNT	0.23	0.02 - 0.50	thou/µL
METHOD : CALCULATED			
ABSOLUTE BASOPHIL COUNT	0.00 Low	0.02 - 0.10	thou/µL
METHOD : CALCULATED			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.6		
METHOD : CALCULATED PARAMETER			

MORPHOLOGY	
RBC	NORMOCYTIC NORMOCHROMIC
METHOD : MICROSCOPIC EXAMINATION	NORMAL MORPHOLOGY
METHOD : MICROSCOPIC EXAMINATION PLATELETS	ADEQUATE
METHOD : MICROSCOPIC EXAMINATION REMARKS METHOD : MICROSCOPIC EXAMINATION	NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED.

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Dr.Miral Gajera Consultant Pathologist



View Report

Page 7 Of 24

35 🗉

View Details





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTO	R: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 ${\sf Email: customercare.ahmedabad@agilus.in}$

Page 8 Of 24





View Report

35 🗆





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : S	ELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID:	DRAWN : RECEIVED : 10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
8800465156		

Test Report Status <u>Final</u> Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BE ERYTHROCYTE SEDIMENTATION RATE (ESR),E			
BLOOD E.S.R METHOD : WESTERGREN METHOD	21 High	0 - 20	mm at 1 hr
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA	WHOLE		
HBA1C	5.3	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD : HPLC ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD-TEST DESCRIPTION :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Dr.Miral Gajera **Consultant Pathologist**



View Details View Report

Page 9 Of 24





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
Test Report Status Final	Results Biological	Reference Interval Units

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-

controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :
1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
 b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera **Consultant Pathologist**





View Report

Page 10 Of 24

View Details





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ASIJF210692321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 09:49:29
NEW DELHI 110030	ABHA NO :	REPORTED :16/02/2024 13:13:57
8800465156		
$\left(\right)$	1	1

Test Report Status Final

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	TYPE O
METHOD : TUBE AGGLUTINATION	
RH TYPE	POSITIVE
METHOD : TUBE AGGLUTINATION	

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



Page 11 Of 24

View Report





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTO	DR: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321	AGE/SEX : 31 Years Female
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
8800465156		
Test Report Status <u>Final</u>	Results Biolog	gical Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP BE	LOW 40FEMALE		·
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	95	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	91	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	202 High	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC		-	
TRIGLYCERIDES	134	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL
	41	< 40 Low	ma/dl
HDL CHOLESTEROL	41	< 40 Low > or = 60 High	mg/dL
CHOLESTEROL LDL	134 High	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL :
NON HDL CHOLESTEROL	161 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	26.8	< or = 30	mg/dL

Dr.Miral Gajera Consultant Pathologist

Page 12 Of 24



View Details





PATIENT NAME : ASIFJAHAN QURESHI		REF. DOCTOR : SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 03 PATIENT ID : ASI CLIENT PATIENT ID: ABHA NO :	21XB001093 AGE/SEX :31 Years Female IJF210692321 DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
CHOL/HDL RATIO LDL/HDL RATIO	4.9 High 3.3 High	3.3 - 4.4 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk

>6.0 High Risk

METHOD : CALCULATED

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for	ASCVD (Ath	erosclerotic cardiovas	cular di	sease) by Lipio	d Association of Ind	lia
Risk Category						
Extreme risk group	A.CAD with	h > 1 feature of high risk	k group			
	B. CAD wit	h > 1 feature of Very hi	igh risk g	roup or recurre	ent ACS (within 1 y	ear) despite LDL-C < or =
		polyvascular disease				
Very High Risk	1. Establish	ed ASCVD 2. Diabetes	s with 2 r	najor risk facto	ors or evidence of en	d organ damage 3.
		mozygous Hypercholes				
High Risk						o evidence of end organ
		CKD stage 3B or 4. 4.		•	•	-
		ium - CAC >300 AU. 7	7. Lipopr	otein a $>/= 50$ r	ng/dl 8. Non stenot	ic carotid plaque
Moderate Risk	5	2 major ASCVD risk factors				
Low Risk	0-1 major ASCVD risk factors					
Major ASCVD (Ath	erosclerotic c	ardiovascular disease)	Risk Fa	ctors		
1. Age $>$ or $=$ 45 year	rs in males and $>$ or $= 55$ years in females 3. Current Cigarette smoking or tobacco use					
2. Family history of p	ry of premature ASCVD 4. High blood pressure					
5. Low HDL						
Newer treatment goals	s and statin in	itiation thresholds bas	sed on th	e risk categor	ies proposed by LA	I in 2020.
Risk Group		Treatment Goals			Consider Drug T	herapy
		LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	Category A	<50 (Optional goal	< 80 (0	Optional goal	>OR = 50	>OR = 80
		< OR = 30)	<or =<="" td=""><td>60)</td><td></td><td></td></or>	60)		
Extreme Risk Group	Category B	<or 30<="" =="" td=""><td>< OR =</td><td>60</td><td>> 30</td><td>>60</td></or>	< OR =	60	> 30	>60
Very High Risk <50 <80				>OR= 50	>OR= 80	

*After an adequate non-pharmacological intervention for at least 3 months.

<70

<100

<100

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

>OR= 70

>OR = 100

>OR= 130*

>OR = 100

>OR=130

>OR=160

<100

<130

<130

LIVER FUNCTION PROFILE, SERUM

High Risk

Low Risk

Moderate Risk

Dr.Miral Gajera Consultant Pathologist



Page 13 Of 24

View Report







PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID : ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
			<i>(</i>
BILIRUBIN, TOTAL	0.82	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.27 High	Upto 0.2	mg/dL
		0.00 1.00	ma/dl
BILIRUBIN, INDIRECT	0.55	0.00 - 1.00	mg/dL
TOTAL PROTEIN METHOD : COLORIMETRIC	7.7	6.4 - 8.3	g/dL
ALBUMIN	4.9	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			
GLOBULIN	2.8	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	1.8	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	22	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	26	0 - 33	U/L
ALKALINE PHOSPHATASE METHOD : COLORIMETRIC	77	35 - 104	U/L
	13	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : UV ASSAY METHOD	184	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	8	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE	0.57 Low	0.60 - 1.10	mg/dL
METHOD : JAFFE ALKALINE PICRATE			
BUN/CREAT RATIO			
BUN/CREAT RATIO	14.04	5.0 - 15.0	

Dr.Miral Gajera Consultant Pathologist



Page 14 Of 24







SIJF210692321 DRAWN RECEIV REPORT	X :31 Years Female I : ED :10/02/2024 09:49:29 TED :16/02/2024 13:13:57
Biological Refere	ED :10/02/2024 09:49:29 ED :16/02/2024 13:13:57 nce Interval Units
Biological Refere	ED :16/02/2024 13:13:57
Biological Refere	ED :16/02/2024 13:13:57
Biological Refere	nce Interval Units
2.4 - 5.7	
	mg/dL
	mg/dL
	mg/dL
6.4 - 8.3	
6.4 - 8.3	
	g/dL
3.5 - 5.2	g/dL
2.0 - 4.1	g/dL
136 - 145	mmol/L
3.3 - 5.1	mmol/L
98 - 106	mmol/L
	136 - 145 3.3 - 5.1

Chloride

Interpretation(s)

Sodium

Dr.Miral Gajera Consultant Pathologist

Potassium

Page 15 Of 24







PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : ASIJF210692321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 09:49:29
NEW DELHI 110030	ABHA NO :	REPORTED :16/02/2024 13:13:57
8800465156		
	1	

Test Re	port	Status	<u>Final</u>
---------	------	--------	--------------

Results

Biological Reference Interval Units

Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II.	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA,dehydration,
vomiting or diarrhea},diabetes	acidosis, dehydration, renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline,hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide,androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

cb>Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice.Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is blockage of the bile ducts, like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts.

unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the

Dr.Miral Gajera Consultant Pathologist



Page 16 Of 24

<u>कित्त</u>ी हैं

View Report

View Details

in a



 \mathbf{B}_{i}



PATIENT NAME: ASIFJAHAN QURESHI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321	AGE/SEX : 31 Years Female DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
Test Report Status Final	Results Biological	Reference Interval Units

liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

Abrevers serving Trypophatasia, Haindarton, Protein denderby, wisons disease.
(b)= GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

ds>Total Protein also known as total protein; a biocherical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease,

Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood

albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CBLCauses of decreased (70> level include Liver disease, SLADE).
CREATININE, SERUM-Higher than normal level may be due to:
Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)
Lower than normal level may be due to:
Matchelic aurdiarea.
CAUSE of Increased levels:
/b>-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2
Matchelic aurdiarea.
Matchelic aurdiarea.
(b) Low Zing interlace OCP Multiple Scienceic

DM,Metabolic syndrome

Social Science (a) Social (a) Socia Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr.Miral Gajera Consultant Pathologist

Ю.



View Report

Page 17 Of 24

View Details





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID:	AGE/SEX : 31 Years Female DRAWN : RECEIVED : 10/02/2024 09:49:29
DELHI NEW DELHI 110030 8800465156	ABHA NO :	REPORTED :16/02/2024 13:13:57
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units

0	CLINICAL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
PHYSICAL EXAMINATION, URINE				
COLOR	Yellow			
APPEARANCE	Clear			
CHEMICAL EXAMINATION, URINE				
PH METHOD : REFLECTANCE SPECTROPHOTOMETRY	6.0	4.7 - 7.5		
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECTROPHOTOMETRY	<=1.005	1.003 - 1.035		
PROTEIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
GLUCOSE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE		
KETONES METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
BLOOD METHOD : REFLECTANCE SPECTROPHOTOMETRY	DETECTED (TRACE)	NEGATIVE		
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NORMAL	NORMAL		
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED		
LEUKOCYTE ESTERASE METHOD : REFLECTANCE SPECTROPHOTOMETRY	DETECTED (+)	NOT DETECTED		

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	2 - 3	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION PUS CELL (WBC'S)	20-30	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION EPITHELIAL CELLS	8-10	0-5	/HPF

Dr.Miral Gajera Consultant Pathologist









PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR	R: SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57
Test Report Status <u>Final</u>	Results Biologi	cal Reference Interval Units

METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	
CRYSTALS	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION		
BACTERIA	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
YEAST	NOT DETECTED	NOT DETECTED
METHOD : MICROSCOPIC EXAMINATION		
REMARKS		
	MICROSCOPIC EXAMINATION OF URINE IS CARRIED OUT ON CENTRIFUGED URINARY SEDIMENT.	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr.Miral Gajera Consultant Pathologist

Page 19 Of 24





View Details





PATIENT NAME: ASIFJAHAN QURESHI	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57

Test Report Status	<u>Final</u>	Results Biological Reference Interval	Units
Test Report Status	<u>rmai</u>	Results Biological Reference filter val	Units

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

ejen

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 ${\sf Email: customercare.ahmedabad@agilus.in}$

Page 20 Of 24



View Report





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321XB001093 PATIENT ID :ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

CYTOLOGY	
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE	
PAPANICOLAOU SMEAR	
TEST METHOD CONVENTIONAL GYNEC CYTOLOGY	
SPECIMEN TYPE TWO UNSTAINED CERVICAL SMEARS RECEIVED	
REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY	
SPECIMEN ADEQUACY SMEARS ARE SATISFACTORY FOR EVALUATION.	
MICROSCOPY SMEARS SHOW PREDOMINANTLY SUPERFICIAL AND INTERMEDIA SQUAMOUS CELLS AGAINST BACKGROUND OF MILD ACUTE INFLAMMATION. ENDOCERVICAL CELLS NOT SEEN ON SMEAR. N EVIDENCE OF DYSPLASIA OR MALIGNANT CELLS SEEN. INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY	

Comments

PAP SMEAR IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE RESULTS SHOULD BE INTERPRETED WITH CAUTION.

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 21 Of 24







Test Report Status

<u>Final</u>



Biological Reference Interval Units

PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : S	ELF
	ACCESSION NO : 0321XB001093	AGE/SEX : 31 Years Female
	PATIENT ID : ASIJF210692321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 10/02/2024 09:49:29
NEW DELHI 110030	ABHA NO :	REPORTED :16/02/2024 13:13:57
8800465156		
(

SPECIALISED CHEMISTRY - HORMONE

Results

SPECIALISED CHEMISIRY - HORMONE					
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE					
THYROID PANEL, SERUM					
ТЗ	116.30	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	ng/dL		
METHOD : ECLIA					
T4	8.47	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70	ıg/dL		
METHOD : ECLIA					
TSH (ULTRASENSITIVE)	1.100	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Association 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000	uIU/mL		
METHOD : ECLIA					

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

Dr.Miral Gajera Consultant Pathologist

Page 22 Of 24





View Report

View Details





PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321XB001093 PATIENT ID : ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57	
Test Report Status <u>Final</u>	Results Biologica	al Reference Interval Units	

active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions	
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)	
					Post Thyroidectomy (4) Post Radio-Iodine treatment	
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid	
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto	
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical	
					inflammation, drugs like amphetamines, Iodine containing drug and	
					dopamine antagonist e.g. domperidone and other physiological reasons.	
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism	
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre	
		_	_	_	(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid	
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4	
					replacement therapy (7) First trimester of Pregnancy	
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism	
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor	
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent	
					treatment for Hyperthyroidism	
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness	
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies	

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

> **End Of Report** Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



View Report

View Details



- <u>0</u>37353

ाः शह



PATIENT NAME : ASIFJAHAN QURESHI	REF. DOCTOR : SELF		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321XB001093 PATIENT ID :ASIJF210692321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :31 Years Female DRAWN : RECEIVED :10/02/2024 09:49:29 REPORTED :16/02/2024 13:13:57	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
 Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

i. Specimen received is insufficient or inappropriate

ii. Specimen quality is unsatisfactory

iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 24 Of 24





View Report

